NEW YORK (Reuters Health)—Patients treated with biologic therapy for rheumatoid arthritis, inflammatory bowel disease and psoriasis don’t appear to be at increased risk of melanoma, according to the results of a systematic review and meta-analysis. However, because the study found trends toward increased melanoma rates with long-term therapy, “a clinically meaningful increase in risk cannot…
Search results for: cancer

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap
Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

The Latest Advances in Sjögren’s, Scleroderma, RA, Gout & More
ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…

Case Report: A Patient’s Clubbing & Arthralgias Resist Diagnosis
A 59-year-old woman presented to our rheumatology clinic with a six-month history of a symmetric polyarthritis. She initially experienced pain in both knees. As time progressed, she began to notice pain in her ankles, hips, shoulders, hands and feet. She experienced joint stiffness lasting for more than 30 minutes every morning. She also described worsening…

Not All Rheumatoid Factor-Positive Tests Mean RA
Angioimmunoblastic T cell lymphoma (AITL) is an aggressive, peripheral T cell, non-Hodgkin’s lymphoma with an incidence of 0.05 cases per 100,000 person-years in the U.S., and it typically manifests in adults older than 60 years.1,2 AITL was previously known as angioimmunoblastic lymphadenopathy with dysproteinemia, immunoblastic lymphadenopathy or lymphogranulomatosis X, due to the hypothesis that the…

Providing the Best Care: Rheumatologists & Professionals Adapt to COVID-19
The new landscape for rheumatologists includes telemedicine, kids out of school and infection-prevention protocols. During the current pandemic, the practice of medicine, research and daily lives are changing to keep providers and patients safe…

The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine
In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

Don’t Forget the Host: COVID-19 Cytokine Storm
The new coronavirus outbreak, COVID-19, reminds us how we have struggled to keep ahead of mutating pathogens through the ages.

Winter 2020’s Awards, Appointments & Announcements in Rheumatology
2019 Lupus Foundation of America Gary S. Gilkeson Career Development Awards Emily Smitherman, MD, assistant professor, pediatric rheumatology, University of Alabama at Birmingham, and Children’s of Alabama, one of four recipients of the Gary S. Gilkeson Career Development Awards, is interested in identifying predictors for differences in disease activity within the pediatric population. To accomplish…

Clinicians Discuss Current & Future Rheumatoid Arthritis Approaches
ATLANTA—When it comes to treating rheumatoid arthritis (RA) patients, most clinicians agree: One size does not fit all. Many treatment options exist, and seldom is there 100% consensus on what the first course of action or general approach should be. In the face of such variability, four clinicians took the stage at the 2019 ACR/ARP…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 83
- Next Page »